eXoZymes, Inc. (NasdaqCM: EXOZ)
Health Care · Biotechnology · US
$7.53
+29.38% today · -40.4% 1Y
eXoZymes, Inc. (NasdaqCM: EXOZ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $53.02M and employs 32 people.
Over the last twelve months the share price has lost 40.4%, trading between 4.35 and 18.40.
Tweenvest scores eXoZymes, Inc. across four factors: quality 26/100. Its strongest factor is quality.
EXOZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $53.02M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.15
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $18.40
- 52-week low
- $4.35
- Avg volume (3M)
- —
- Shares outstanding
- 9.11M
- Employees
- 32
- Next earnings
- —
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
- ISIN
- US4618741098
- Founded
- 2014
- Listed since
- Nov 13, 2024
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.